Teva: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia, was approved based on the SOLARIS trial. The trial showed significant symptom reduction compared to placebo. Dr. Christoph Correll, principal investigator, highlighted the benefits of long-acting injectables in reducing relapse and improving patient outcomes. Weltruza's subcutaneous administration aims to address patient reluctance and resource limitations of previous treatments.

Sanofi and Teva's IBD drug, duvakitug, showed long-term clinical remission in a Phase IIb trial. Analysts highlight its high potency and potential advantages over competitors. MSD and Roche have also invested heavily in anti-TL1A drugs, with MSD's tulisokibart and Roche's afimkibart in Phase III trials.

Teva (TEVA) and Sanofi (SNY) reported positive Phase 2b data for duvakitug, showing sustained benefits in ulcerative colitis and Crohn's disease through Week 44. Clinical remission rates varied by dose, with higher rates observed at 900 mg. The drug was generally well tolerated. Both companies are advancing duvakitug into Phase 3 studies. SNY is up 4.11% at $41.19, while TEVA is down 0.41% at $41.14.

Teva Pharmaceuticals and Sanofi reported positive long-term data for duvakitug, showing sustained efficacy in ulcerative colitis and Crohn's disease trials. The 44-week study met multiple endpoints. Teva's shares rose 0.87% to $41.64 in pre-market trading. The drug is under clinical investigation and not yet approved.

Teva Pharmaceuticals and Sanofi reported positive 44-week data for duvakitug, their investigational treatment for ulcerative colitis (UC) and Crohn's disease (CD). The drug showed high rates of clinical remission, response, and endoscopic improvement in both conditions, with a favorable safety profile. Results were presented at UEG Week 2026, and phase 3 trials are ongoing.

Teva Pharmaceuticals and Sanofi presented positive 44-week data from the RELIEVE UCCD phase 2b study, showing duvakitug maintained efficacy in ulcerative colitis (UC) and Crohn's disease (CD). The drug achieved high rates of clinical remission, response, and endoscopic improvement. Duvakitug was well-tolerated, with a safety profile consistent with the induction phase. The companies are advancing duvakitug in phase 3 trials for UC and CD, and a phase 2 study for hidradenitis suppurativa.